Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming

About Michael Silber

This author has not yet filled in any details.
So far Michael Silber has created 2722 blog entries.

Vermont

Gov. Phil Scot (R) signed NACDS priority legislation H.588 on June 8 to expand pharmacist test and treat authority across four conditions – Flu, Strep, COVID and HIV. The legislation received significant support from NACDS and its membership operating in the state and was widely endorsed by numerous in-state health groups and the Vermont Department of Health Access (DVHA). DVHA made recent references to the value of pharmacist test and treat services in its rollout of Rural Health Transformation Program (RHTP) grants. 

For more information, please contact NACDS’ Mike Sargent at 207-272-6435.

2026-06-11T17:53:27-04:00June 11, 2026|Vermont|

California

The Department of Health Care Services posted the following on the Medi-Cal Rx Web Portal: 

Also in California, the Board of Pharmacy posted the agendas for the following committee meetings:  

  • Communications & Public Education Committee Meeting – June 10 
  • Enforcement & Compounding Committee Meeting – June 10 
  • Legislation & Regulation Committee – June 11 
  • Licensing Committee Meeting – June 11  

Finally in California, the Board of Pharmacy published the May 2026 issue of "The Script". 

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2026-06-05T10:29:32-04:00June 5, 2026|California|

Colorado

On June 2, Gov. Jared Polis (D) signed HB 26-1336, legislation supported by NACDS, that expands access to pharmacy healthcare services and authorizes payment for these services. The bill enables children aged 12 years and older to receive test-and-treat services directly at pharmacies. Additionally, it permits pharmacy technicians, under the supervision of a pharmacist, to perform final product verification and other technical, non-discretionary tasks. 

Also in Colorado, the Department of Health Care Policy and Financing (HCPF) posted new information on the federal-level implementation of H.R. 1 because members and providers will be affected by these changes. HCPF updated the FAQs for stakeholders and for members, and created a work requirements screening tool. Also available are overview pages about H.R. 1 on both the Health First Colorado site and the HCPF site.  

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2026-06-05T10:29:01-04:00June 5, 2026|Colorado|

Illinois

The Department of Healthcare and Family Services issued a Provider Notice RE: Rybelsus Tablets to Ozempic Tablets. This change will apply to both the fee-for-service (FFS) program and Managed Care Organizations (MCOs) plans. There are no changes to Ozempic injections. 

Novo Nordisk informed the Department of Healthcare and Family Services (HFS) that it will discontinue all strengths of Rybelsus tablets, requiring patients to be transitioned to Ozempic tablets. Beginning in May 2026, shipments of Rybelsus tablets to wholesalers will cease, with existing inventory expected to become limited starting in July 2026.  

Please see notice for details. Questions regarding this notice may be directed to the Bureau of Professional and Ancillary Services at 877-782-5565 or the applicable MCO.  

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

2026-06-05T10:27:29-04:00June 5, 2026|Illinois|
Go to Top